Recursion Pharmaceuticals Accounts Payable

Recursion Pharmaceuticals (RXRX) currently reports a accounts payable of $20M as of March 2026. That compares with $25M in the prior-year period — down 18.9% year over year. Use the charts on this page to explore Recursion Pharmaceuticals's accounts payable history and peer comparisons.

Recursion Pharmaceuticals's accounts payable decreased from $25M to $20M — a 18.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recursion Pharmaceuticals reported $20M in accounts payable as of March 2026. That compares with $25M in the prior-year period — down 18.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Recursion Pharmaceuticals, and consider following RXRX for alerts when major investors trade the stock.

Recursion Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RXRX with unrelated industries.